Philip G. de Groot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip G. de Groot has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
J J Sixma
19 shared publicationsR. H. W. M. Derksen
Department of Rheumatology and Clinical Immunology, Utrecht University, University Medical Centre Utrecht, Utrecht
8 shared publicationsR H Derksen
7 shared publicationsH K Nieuwenhuis
6 shared publications- Rolf T. Urbanus
Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
5 shared publications D A Horbach
Department of Haematology, University Hospital Utrecht, The Netherlands
4 shared publications
Latest Publications
- 1 August 2010
- Vol. 30 (3) , 139-43
Antiphospholipid syndrome. Current insights into laboratory diagnosis and pathophysiology.
The antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) in the plasma of patients with vascular thrombosis, recurrent complications of pregnancy, or both (1, 2). The presence of aPL in plasma of patients can be detected with either a prolongation of phospholipid dependent coagulation tests (lupus anticoagulant, LAC), or with solid phase immune assays against the protein beta2-glycoprotein I (beta2-GPI) or the phospholipid cardiolipin (anti-beta2-GPI antibody ELISA and anti-cardiolipin antibody ELISA, respectively) (3). For a long time there was a lot of confusion on who had the syndrome and who not. To solve this dispute, an international consensus meeting was organized in Sapporo in 1999 to formulate classification criteria for patients with the antiphospholipid syndrome (4). These criteria have been updated in 2004 at another international consensus meeting in Sydney (5). The classification criteria were defined for scientific purposes and were aimed to be used as inclusion criteria in patient related studies. They were specifically not defined for diagnostic purposes. However, current practice is that these criteria are used as a diagnostic tool. This is very unfortunate because the specificity of the different aPL assays to detect the clinical manifestations that characterize APS are disputable. One of the aims of defining the criteria was to initiate studies to determine the value of the different anti-phospholipid antibody assays to serve as biomarker for the risk of thrombosis and pregnancy morbidity. The recent progress made on this important topic will be discussed.
- 1 August 2010
- Vol. 30 (3) , 139-43
Antiphospholipid syndrome. Current insights into laboratory diagnosis and pathophysiology.
The antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) in the plasma of patients with vascular thrombosis, recurrent complications of pregnancy, or both (1, 2). The presence of aPL in plasma of patients can be detected with either a prolongation of phospholipid dependent coagulation tests (lupus anticoagulant, LAC), or with solid phase immune assays against the protein beta2-glycoprotein I (beta2-GPI) or the phospholipid cardiolipin (anti-beta2-GPI antibody ELISA and anti-cardiolipin antibody ELISA, respectively) (3). For a long time there was a lot of confusion on who had the syndrome and who not. To solve this dispute, an international consensus meeting was organized in Sapporo in 1999 to formulate classification criteria for patients with the antiphospholipid syndrome (4). These criteria have been updated in 2004 at another international consensus meeting in Sydney (5). The classification criteria were defined for scientific purposes and were aimed to be used as inclusion criteria in patient related studies. They were specifically not defined for diagnostic purposes. However, current practice is that these criteria are used as a diagnostic tool. This is very unfortunate because the specificity of the different aPL assays to detect the clinical manifestations that characterize APS are disputable. One of the aims of defining the criteria was to initiate studies to determine the value of the different anti-phospholipid antibody assays to serve as biomarker for the risk of thrombosis and pregnancy morbidity. The recent progress made on this important topic will be discussed.
- 1 July 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (7) , 1538-1544
Platelets express three different splice variants of ApoER2 that are all involved in signaling
- 1 July 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (7) , 1538-1544
Platelets express three different splice variants of ApoER2 that are all involved in signaling
- 1 February 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (2) , 369-377
Platelet adhesion to dimeric β2‐glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2′
- 1 February 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (2) , 369-377
Platelet adhesion to dimeric β2‐glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2′
- 1 November 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (11) , 1468-1472
Annexin A5 polymorphism (−1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome
Background: Annexin A5 is thought to have a role in the pathophysiology of the antiphospholipid syndrome (APS)—a syndrome characterised by recurrent thrombosis and pregnancy morbidity. Objective: To investigate whether anti-annexin A5 immunoglobulin (Ig)M or IgG antibodies, or the −1C→T polymorphism of annexin A5, is a risk factor for thrombosis or miscarriage, and whether the −1C→T polymorphism is correlated with APS. Methods: A cohort study was carried out with a population of 198 patients with primary APS, systemic lupus erythematosus or lupus-like disease. For the detection of anti-annexin A5 antibodies and the measurement of annexin A5 plasma levels, ELISA-type methods were used. The annexin A5 −1C→T mutation was detected by restriction fragment length polymorphism. Results: 71 patients were positive for annexin A5 IgM or IgG antibodies, of whom 53 patients were positive for anti-annexin A5 IgG antibodies and 27 of 198 patients were positive for anti-annexin A5 IgM antibodies. The prevalence of IgM or IgG anti-annexin A5 antibodies was not significantly associated with thrombosis or miscarriage on multivariate analysis. The prevalence of the −1C→T mutation in the annexin A5 gene (46/198 patients) was significantly associated with miscarriage (odds ratio 2.7, 95% confidence interval 1.1 to 6.7, independent risk factor). Conclusion: The detection of anti-annexin A5 antibodies does not seem relevant for estimating the risk for thrombosis or miscarriage in APS. The −1C→T mutation was an independent risk factor for miscarriage, which is independent of APS.
- 1 November 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (11) , 1468-1472
Annexin A5 polymorphism (−1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome
Background: Annexin A5 is thought to have a role in the pathophysiology of the antiphospholipid syndrome (APS)—a syndrome characterised by recurrent thrombosis and pregnancy morbidity. Objective: To investigate whether anti-annexin A5 immunoglobulin (Ig)M or IgG antibodies, or the −1C→T polymorphism of annexin A5, is a risk factor for thrombosis or miscarriage, and whether the −1C→T polymorphism is correlated with APS. Methods: A cohort study was carried out with a population of 198 patients with primary APS, systemic lupus erythematosus or lupus-like disease. For the detection of anti-annexin A5 antibodies and the measurement of annexin A5 plasma levels, ELISA-type methods were used. The annexin A5 −1C→T mutation was detected by restriction fragment length polymorphism. Results: 71 patients were positive for annexin A5 IgM or IgG antibodies, of whom 53 patients were positive for anti-annexin A5 IgG antibodies and 27 of 198 patients were positive for anti-annexin A5 IgM antibodies. The prevalence of IgM or IgG anti-annexin A5 antibodies was not significantly associated with thrombosis or miscarriage on multivariate analysis. The prevalence of the −1C→T mutation in the annexin A5 gene (46/198 patients) was significantly associated with miscarriage (odds ratio 2.7, 95% confidence interval 1.1 to 6.7, independent risk factor). Conclusion: The detection of anti-annexin A5 antibodies does not seem relevant for estimating the risk for thrombosis or miscarriage in APS. The −1C→T mutation was an independent risk factor for miscarriage, which is independent of APS.
- 1 August 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (8) , 1680-1690
Interaction of β2-glycoprotein I with members of the low density lipoprotein receptor family
- 1 August 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (8) , 1680-1690
Interaction of β2-glycoprotein I with members of the low density lipoprotein receptor family
- 1 July 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (7) , 1619-1621
High‐avidity anti‐β2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low‐avidity anti‐β2 glycoprotein I antibodies
- 1 July 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (7) , 1619-1621
High‐avidity anti‐β2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low‐avidity anti‐β2 glycoprotein I antibodies
- 1 January 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (1) , 41-43
The importance of measuring anticardiolipin antibodies
- 1 January 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (1) , 41-43
The importance of measuring anticardiolipin antibodies
- 8 August 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (8) , 1854-1860
Pathophysiology of the antiphospholipid syndrome
- 8 August 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (8) , 1854-1860
Pathophysiology of the antiphospholipid syndrome
- Open Access
- 8 July 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (9) , 1993-1997
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis
- 8 July 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (9) , 1993-1997
Open AccessLupus anticoagulants and the risk of a first episode of deep venous thrombosis